Fundamental Analysis of ADVERUM BIOTECHNOLOGIES INC(NASDAQ:ADVM) stock

Fundamental Rating

ADVM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 565 industry peers in the Biotechnology industry. ADVM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ADVM is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ADVM has reported negative net income.

In the past year ADVM has reported a negative cash flow from operations.

ADVM had negative earnings in each of the past 5 years.

In the past 5 years ADVM always reported negative operating cash flow.

1.2 Ratios

ADVM has a Return On Assets of -39.35%. This is comparable to the rest of the industry: ADVM outperforms 58.47% of its industry peers.

With a decent Return On Equity value of -59.43%, ADVM is doing good in the industry, outperforming 61.50% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-39.35%
ROE	-59.43%
ROIC	N/A

ROA(3y)-50.31%

ROA(5y)-40.85%

ROE(3y)-90.51%

ROE(5y)-67.09%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ADVM so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ADVM does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ADVM has been increased compared to 1 year ago.

The number of shares outstanding for ADVM has been increased compared to 5 years ago.

There is no outstanding debt for ADVM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -5.14, we must say that ADVM is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of ADVM (-5.14) is worse than 62.03% of its industry peers.

There is no outstanding debt for ADVM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-5.14

ROIC/WACCN/A

WACC10.43%

2.3 Liquidity

A Current Ratio of 7.99 indicates that ADVM has no problem at all paying its short term obligations.

ADVM has a Current ratio of 7.99. This is in the better half of the industry: ADVM outperforms 73.44% of its industry peers.

A Quick Ratio of 7.99 indicates that ADVM has no problem at all paying its short term obligations.

ADVM has a better Quick ratio (7.99) than 73.97% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	7.99
Quick Ratio	7.99

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 52.46% over the past year.

Measured over the past years, ADVM shows a quite strong growth in Revenue. The Revenue has been growing by 17.43% on average per year.

EPS 1Y (TTM)52.46%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%60.61%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y17.43%

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 10.76% on average over the next years. This is quite good.

The Revenue is expected to grow by 59.41% on average over the next years. This is a very strong growth

EPS Next Y55.44%

EPS Next 2Y25.07%

EPS Next 3Y17.02%

EPS Next 5Y10.76%

Revenue Next Year-82.95%

Revenue Next 2Y54.17%

Revenue Next 3Y76.91%

Revenue Next 5Y59.42%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADVM. In the last year negative earnings were reported.

Also next year ADVM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ADVM's earnings are expected to grow with 17.02% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y25.07%

EPS Next 3Y17.02%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ADVM!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ADVERUM BIOTECHNOLOGIES INC

NASDAQ:ADVM (11/22/2024, 8:21:49 PM)

After market: 6.04 0 (0%)

6.04

+0.29 (+5.04%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap125.63M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-39.35%
ROE	-59.43%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	7.99
Quick Ratio	7.99
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)52.46%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y55.44%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ADVERUM BIOTECHNOLOGIES INC (ADVM)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens